Navigator Medicines unveiled its plans to develop novel medicines for complex, heterogeneous autoimmune diseases on 27 August, revealing that it has raised $100m in series A funding from RA Capital Management and Forbion. In tandem, the privately held biotech formally announced a licensing agreement with IMBiologics Corp.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?